Rigel Pharmaceuticals Inc.
06/17/2026 | Press release | Distributed by Public on 06/17/2026 14:06
Asset Transaction (Form 8-K)
Item 2.01. Completion of Acquisition or Disposition of Assets.
As previously disclosed in the Current Report on Form 8-K filed by Rigel Pharmaceuticals, Inc. (the "Company") on May 12, 2026, the Company entered into a License Agreement (the "License Agreement") with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. (collectively, the "Licensors"), pursuant to which the Licensors granted the Company exclusive, global rights to develop, manufacture and commercialize VEPPANU™ (vepdegestrant) and related products worldwide.
Following the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the satisfaction of the other closing conditions under the License Agreement, the License Agreement became effective and the transactions contemplated thereby were completed. In connection therewith, the Company paid the Licensors a one-time upfront payment of $70.0 million.
Rigel Pharmaceuticals Inc. published this content on June 17, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 17, 2026 at 20:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]